Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02471144 · ClinicalTrials.gov registry record · Phase 3
Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis
A Phase 3 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 162
- Enrollment target
NCT02471144 is a Phase 3 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 162 participants.
The verdict
NCT02471144, a Phase 3 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 162 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to \<18 years were enrolled, of which at least 30 were 6 years to \<12 years old. Subjects were enrolled at approximately 70 study sites worldwide.
Interventions
- BIOLOGICAL Experimental : Secukinumab low dose
- BIOLOGICAL Experimental: Secukinumab high dose
- BIOLOGICAL Placebo Comparator: Secukinumab Placebo
- BIOLOGICAL Active Comparator: Etanercept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 162 participants |
| Start Date | 2015-09-29 |
| Est. Completion | 2023-03-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02471144
The ClinicalTrials.gov registry entry for NCT02471144 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 162 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Experimental : Secukinumab low dose is the first listed.
NCT02471144 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02471144 about?
NCT02471144 is a clinical study titled "Pediatric Study in Children and Adolescents With Severe Plaque Psoriasis". This was a multicenter, randomized, double-blind, placebo- and active-controlled (etanercept in single blinded arm) study in pediatric subjects aged 6 years to less than 18 years with severe chronic plaque psoriasis. Approximately 160 subjects aged 6 years to \<18 years were enrolled, of which at le...
What is the current status of trial NCT02471144?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 162 participants. The study started on 2015-09-29. Estimated completion is 2023-03-30.
What interventions are being tested in trial NCT02471144?
The interventions under investigation include: Experimental : Secukinumab low dose (BIOLOGICAL), Experimental: Secukinumab high dose (BIOLOGICAL), Placebo Comparator: Secukinumab Placebo (BIOLOGICAL), Active Comparator: Etanercept (BIOLOGICAL).
Who is sponsoring clinical trial NCT02471144?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.